Immco Diagnostics, Inc. Kevin Lawson VP Regulatory Affairs 9870 Hollingson Rd Clarence, New York 14031

Re: K163177 Trade/Device Name: ImmuLisa Enhanced Gliadin IgA Antibody ELISA, ImmuLisa Enhanced Gliadin IgG Antibody ELISA Regulation Number: 21 CFR 866.5750 Regulation Name: Radioallergosorbent (RAST) immunological test system Regulatory Class: Class II Product Code: MST Dated: July 5, 2017 Received: July 7, 2017

Dear Kevin Lawson:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR

Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and Part 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

# Kelly Oliner -S

For   
Leonthena R. Carrington, M.S., MBA, MT   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) K163177

Device Name ImmuLisaTM Enhanced Gliadin IgA Antibody ELISA

ImmuLisaTM Enhanced Gliadin IgG Antibody ELISA

Indications for Use (Describe)   
Enkben ss ELIA)orhequaliaivqanivetec In   
  
with other laboratory and clinical findings

Enikobet assys ELISA)orhequalitaivmiquanttativetectionIgGn with other laboratory and clinical findings

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

Turenolctiotitat veror ncl time to reviewinstructions, search existing data sources, gatherand maintain thedata needed and coplete an review the colectioninformation Send comments regarding this burden estimate r anyother aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary

Submitter:   
Address:   
Phone Number:   
Contact:   
Summary Prepared: Immco Diagnostics, Inc.   
60 Pineview Dr., Buffalo, NY 14228 716-691-0091 ext. 110   
Kevin Lawson   
7-27-2017

Device Name:

Common Name:   
Product Code:   
Substantially Equivalent to:

ImmuLisa™ Enhanced Gliadin IgA Antibody ELISA ImmuLisa™ Enhanced Gliadin IgG Antibody ELISA Anti-Gliadin IgA or IgG Antibody (AGA) ELISA Antibodies, Gliadin [MST] IMMCO Gliadin (AGA) IgA ELISA IMMCO Gliadin (AGA) IgG ELISA

General Description: Celiac Disease (CD) and dermatitis herpetiformis (DH) are autoimmune gastrointestinal and skin disorders that may occur in genetically susceptible individuals triggered by the ingestion of gluten containing grains such as wheat, barley and rye. The classical symptoms of CD include diarrhea, weight loss and malnutrition. Dermatitis herpetiformis is chronic bullous disease characterized by the formation of subepidermal blisters. Only a small percentage of patients with CD present with classical symptoms. The most common serologic tests for the screening of CD or DH are the immunofluorescence method of detecting endomysial antibodies (EMA) and ELISA methods of detecting antibodies to tissue transglutaminase (tTG) and gliadin. The limitation of the EMA and tTG immunoassays is that both immunoassays detect IgA antibodies, hindering identification of IgA deficient patients with CD. IgG gliadin antibody tests are important towards the diagnosis of CD in patients who are IgA deficient. Studies show that $1 - 2 \%$ of the general population is IgA deficient and that the incidence of CD in IgA deficient subjects is significant, hence the need for specific tests. In addition to the native Gliadin assay, Gliadin peptide based assays have shown promising results in addressing the limitations of current assays. This current immunoassay for gliadin antibodies incorporates a native gliadin protein for sensitive and specific detection of IgA or IgG isotype antibodies with a high degree of reliability.

This test is performed as a solid phase immunoassay. Microwells are coated with native purified Gliadin antigen. Controls, calibrators and patient sera are incubated in the antigen coated wells to allow specific antibodies present in the serum to bind to the gliadin antigen. Bound antibodies are detected by adding an enzyme labeled anti-human IgA or IgG conjugate. Specific enzyme substrate (TMB) is then added and the presence of antibodies is detected by a color change that is read by a spectrophotometer at $4 5 0 \mathsf { n m }$ . Results are expressed in ELISA units per milliliter $( \mathsf { E U } / \mathsf { m l } )$ ) and reported as positive or negative.

Intended Use: Enzyme linked immunosorbent assays (ELISA) for the qualitative or semi-quantitative detection of IgA or IgG anti-gliadin antibodies in human serum to aid in the diagnosis of patients with celiac disease or dermatitis herpetiformis in conjunction with other laboratory and clinical findings.

Similarities and Differences: Both kits use native purified Gliadin coated on 96 well plates to detect IgA or IgG Gliadin antibodies with anti-human IgA or IgG conjugate and substrate. Both kits test human serum. Semi-quantitative results are reported in $\mathsf { E U } / \mathsf { m } |$ for both kits. The Enhanced kit utilizes a HRP anti-human IgA or IgG conjugate and TMB substrate, while the predicate AGA kit uses an alkaline phosphatase IgA or IgG conjugate and pNPP substrate. The Enhanced kit utilizes a 5 point calibrator curve with a borderline / indeterminate range of 20-25 EU/ml while the predicate AGA kit uses a 4 point calibrator curve with a cutoff of 20 units and no borderline range.

# Non-clinical Tests:

Method Comparison: Both kits were tested with well-characterized CD and DH subjects and disease controls.

<table><tr><td colspan="3"></td><td colspan="2">Predicate AGA IgA</td></tr><tr><td></td><td></td><td>Pos</td><td>Neg</td><td>Total</td></tr><tr><td>Immco</td><td>Pos</td><td>96</td><td>17</td><td>113</td></tr><tr><td>AGA IgA</td><td>Borderline</td><td>10</td><td>12</td><td>22</td></tr><tr><td>ELISA</td><td>Neg</td><td>3</td><td>262</td><td>265</td></tr><tr><td></td><td>Total</td><td>109</td><td>291</td><td>400</td></tr></table>

<table><tr><td colspan="2">Disease Associated Specimens:</td><td colspan="2">230 170</td></tr><tr><td colspan="2">Disease Control Specimens:</td><td colspan="2"></td></tr><tr><td colspan="2">Borderline considered positive</td><td></td></tr><tr><td colspan="2">Positive % Agreement</td><td>97.2% (95% CI 91.6% - 99.3%)</td></tr><tr><td colspan="2">Negative % Agreement</td><td>90.0% (95% CI 85.9% - 93.1%)</td></tr><tr><td colspan="2">Overall % Agreement</td><td>92.0% (95% CI 88.9% - 94.3%)</td></tr><tr><td colspan="3">Borderline considered negative</td></tr><tr><td colspan="2">Positive % Agreement</td><td>88.1% (95% CI 80.1% - 93.2%)</td></tr><tr><td colspan="2">Negative % Agreement</td><td>94.2% (95% CI 90.6% - 96.5%)</td></tr><tr><td colspan="2">Overall % Agreement</td><td>92.5% (95% CI 89.5% - 94.7%)</td></tr><tr><td colspan="2"></td></tr><tr><td></td><td>Pos</td><td>Neg Total</td></tr><tr><td>Immco Pos Borderline</td><td>190</td><td>10 200</td></tr><tr><td>AGA IgG</td><td>9</td><td>4 213</td></tr><tr><td>ELISA Neg</td><td>6</td><td>240 246</td></tr><tr><td>Total</td><td>205</td><td>254 459</td></tr><tr><td colspan="2">Disease Associated Specimens: 246 Disease Control Specimens:</td></tr><tr><td colspan="2">213 Borderline considered positive</td></tr><tr><td colspan="2">Positive % Agreement 97.1% (95% CI 93.4% - 98.8%)</td></tr><tr><td colspan="2">Negative % Agreement</td></tr><tr><td colspan="2">94.5% (95% CI 90.7% - 96.8%)</td></tr><tr><td colspan="2">Overall % Agreement 95.6% (95% CI 93.4% - 97.2%)</td></tr><tr><td colspan="2"></td></tr><tr><td colspan="2">Borderline considered negative (95% CI 88.0% - 95.7%)</td></tr><tr><td colspan="2">Positive % Agreement 92.7%</td></tr><tr><td>Negative % Agreement</td><td>96.1% (95% CI 92.7% - 98.0%)</td></tr><tr><td></td><td></td></tr><tr><td>Overall % Agreement</td><td>94.6% (95% CI 92.1% - 96.3%)</td></tr></table>

Cross Reactivity: A total of 456 sera from individuals with other potentially cross-reactive autoimmune disorders were selected to test for gliadin antibodies using the ImmuLisa™ assay. The results appear below.

<table><tr><td rowspan="2">Disease</td><td colspan="3">Gliadin IgA</td><td colspan="2">Gliadin IgG</td></tr><tr><td>n</td><td>n Pos</td><td>% Pos</td><td>n Pos</td><td>% Pos</td></tr><tr><td>Rheumatoid Arthritis</td><td>30</td><td>1</td><td>3.3%</td><td>0</td><td>0.0%</td></tr><tr><td>Graves&#x27; disease</td><td>15</td><td>1</td><td>6.7%</td><td>0</td><td>0.0%</td></tr><tr><td>Hashimoto&#x27;s thyroiditis</td><td>15</td><td>0</td><td>0.0%</td><td>1</td><td>6.7%</td></tr><tr><td>Systemic lupus erythematosus</td><td>30</td><td>2</td><td>6.7%</td><td>3</td><td>10.0%</td></tr><tr><td>Granulomatosis with polyangiitis</td><td>30</td><td>0</td><td>0.0%</td><td>1</td><td>3.3%</td></tr><tr><td>Systemic sclerosis</td><td>30</td><td>0</td><td>0.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Ulcerative Colitis</td><td>25</td><td>0</td><td>0.0%</td><td>1</td><td>4.0%</td></tr><tr><td>Crohn&#x27;s disease</td><td>25</td><td>1</td><td>4.0%</td><td>2</td><td>8.0%</td></tr><tr><td>Rubella</td><td>20</td><td>0</td><td>0.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Herpes simplex virus Type 1</td><td>20</td><td>0</td><td>0.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Herpes simplex virus Type 2</td><td>20</td><td>0</td><td>0.0%</td><td>3</td><td>15.0%</td></tr><tr><td>Cytomegalovirus</td><td>20</td><td>0</td><td>0.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Toxoplasmosis</td><td>20</td><td>0</td><td>0.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Lyme disease</td><td>36</td><td>0</td><td>0.0%</td><td>3</td><td>8.3%</td></tr><tr><td>Autoimmune hepatitis</td><td>30</td><td>0</td><td>0.0%</td><td>1</td><td>3.3%</td></tr><tr><td>Primary biliary cirrhosis</td><td>50</td><td>4</td><td>8.0%</td><td>3</td><td>6.0%</td></tr><tr><td>Helicobacter pylori</td><td>40</td><td>3</td><td>7.5%</td><td>3</td><td>7.5%</td></tr><tr><td>Total</td><td>456</td><td>12</td><td>2.6%</td><td>21</td><td>4.6%</td></tr></table>

# Precision

Precision was tested with positive specimens selected throughout the range of the assay. Seven patients were run in duplicate, twice per day for 20 days $\scriptstyle 1 = 8 0$ replicates per sample). Assays were run by two operators on two different sets of equipment.

# Gliadin IgA

Gliadin IgG   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>TotalImprecision</td><td rowspan=1 colspan=2>Within run(Repeatability)</td><td rowspan=1 colspan=2>Between days</td><td rowspan=1 colspan=2>Between Runs</td></tr><tr><td rowspan=1 colspan=1>S#</td><td rowspan=1 colspan=1>EU/ml</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>67.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>93.2</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>143.5</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>3.1</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>TotalImprecision</td><td rowspan=1 colspan=2>Within run(Repeatability)</td><td rowspan=1 colspan=2>Between days</td><td rowspan=1 colspan=2>Between Runs</td></tr><tr><td rowspan=1 colspan=1>S#</td><td rowspan=1 colspan=1>EU/ml</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>19.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>23.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>44.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>96.8</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>153.4</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>7.6</td></tr></table>

# Qualitative Reproducibility

80 replicates of samples in the low negative range, near the cutoff, in the moderate positive range, and approximately $+ / - 2 0 \%$ of the assay cutoffs for each AGA isotype were performed to determine qualitative reproducibility. One sample near the cutoff yielded $5 1 . 3 \%$ and $5 7 . 5 \%$ agreement on Gliadin IgA and Gliadin IgG respectively, all remaining specimens produced $100 \%$ qualitative agreement.

# Inter-lot Reproducibility

Inter-lot reproducibility was tested with multiple endogenous specimens selected throughout the range of the assay. Five samples were tested in replicates of 5 on three different lots over the course of five days. There was no recalibration of this equipment over the course of this study. Five samples were tested in replicates of five on three separate assay lots for 5 days.

Gliadin IgA   

<table><tr><td colspan="4">Repeatability</td><td colspan="2">Within Lot</td><td colspan="2">Reproducibility</td></tr><tr><td>Mean</td><td>SD</td><td>CV</td><td>SD</td><td>CV</td><td>SD</td><td>CV</td></tr><tr><td>9.87</td><td>0.36</td><td>3.7%</td><td>0.74</td><td>7.5%</td><td>0.74</td><td>7.5%</td></tr><tr><td>22.56</td><td>1.36</td><td>6.0%</td><td>1.70</td><td>7.5%</td><td>1.78</td><td>7.9%</td></tr><tr><td>35.19</td><td>0.81</td><td>2.3%</td><td>2.36</td><td>6.7%</td><td>2.36</td><td>6.7%</td></tr><tr><td>77.90</td><td>1.60</td><td>2.1%</td><td>5.72</td><td>7.3%</td><td>5.88</td><td>7.6%</td></tr><tr><td>149.72</td><td>6.62</td><td>4.4%</td><td>10.74</td><td>7.2%</td><td>11.65</td><td>7.8%</td></tr></table>

Gliadin IgG   

<table><tr><td colspan="4">Repeatability</td><td colspan="2">Within Lot</td><td colspan="2">Reproducibility</td></tr><tr><td>Mean</td><td>SD</td><td>CV</td><td>SD</td><td>CV</td><td>SD</td><td></td><td>CV</td></tr><tr><td>16.13</td><td>0.59</td><td>3.7%</td><td>1.49</td><td>9.2%</td><td>1.49</td><td></td><td>9.2%</td></tr><tr><td>22.59</td><td>1.01</td><td>4.5%</td><td>2.06</td><td>9.1%</td><td>2.06</td><td></td><td>9.1%</td></tr><tr><td>35.48</td><td>1.18</td><td>3.3%</td><td>3.10</td><td>8.7%</td><td>3.10</td><td></td><td>8.7%</td></tr><tr><td>87.31</td><td>2.69</td><td>3.1%</td><td>5.37</td><td>6.2%</td><td>5.66</td><td></td><td>6.5%</td></tr><tr><td>122.87</td><td>4.97</td><td>4.0%</td><td>9.99</td><td>8.1%</td><td>11.29</td><td></td><td>9.2%</td></tr></table>

# Inter-site Reproducibility

Site to site reproducibility was tested with multiple endogenous specimens selected throughout the range of the assay. Five samples were tested in replicates of 5 in three different sites over the course of five days. There was no recalibration of this equipment over the course of this study.

Gliadin IgA   

<table><tr><td rowspan=2 colspan=7>Repeatability            Within Lot           ReproducibilityMean      SD       CV       SD       CV       SD       CV</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td></tr><tr><td rowspan=1 colspan=1>10.00</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>0.83</td><td rowspan=4 colspan=1>8.3%9.4%8.6%9.6%</td></tr><tr><td rowspan=1 colspan=1>22.73</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1.40</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>2.13</td></tr><tr><td rowspan=1 colspan=1>47.72</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>4.10</td></tr><tr><td rowspan=1 colspan=1>88.38</td><td rowspan=1 colspan=1>4.70</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>7.79</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>8.46</td></tr><tr><td rowspan=1 colspan=1>146.18</td><td rowspan=1 colspan=1>5.09</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>11.99</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>12.79</td><td rowspan=1 colspan=1>8.8%</td></tr></table>

Gliadin IgG   

<table><tr><td rowspan=2 colspan=7>Repeatability            Within Lot           ReproducibilityMean      SD       CV       SD       CV       SD       CV</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td></tr><tr><td rowspan=1 colspan=1>13.99</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>1.28</td><td rowspan=5 colspan=1>9.1%8.5%7.0%8.2%9.2%</td></tr><tr><td rowspan=1 colspan=1>24.12</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=2 colspan=1>2.062.36</td></tr><tr><td rowspan=1 colspan=1>33.88</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>69.97</td><td rowspan=1 colspan=1>2.85</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>5.77</td></tr><tr><td rowspan=1 colspan=1>151.12</td><td rowspan=1 colspan=1>5.27</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>10.82</td><td rowspan=1 colspan=1>7.2%</td><td rowspan=1 colspan=1>13.95</td></tr></table>

# Limit of Detection / Limit of Blank / Limit of Quantitation

The limits of blank (LoB) and limits of detection (LoD) were determined based on 60 replicates of the blank and 10 replicates each of 6 lowlevel (NHS) samples. LoB was determined to be $2 . 2 \ : \mathsf { E U } / \mathsf { m l }$ for IgA and 1.6 EU/ml for IgG. LoD was determined to be $3 . 6 \ : \mathsf { E U } / \mathsf { m l }$ for IgA and $2 . 8 \ : \mathsf { E U } / \mathsf { m l }$ for IgG. The limits of quantitation (LoQ) were determined by testing four low level samples in replicates of four. LoQ was determined to be $7 . 5 \ : \mathsf { E U } / \mathsf { m l }$ for IgA and 4.6 EU/ml for IgG.

# Linearity and Recovery

Linearity and recovery were tested by diluting positive specimens through the assay range in equidistant dilutions and comparing actual vs. expected results. The linear range of the assay was determined be 7.5 (LoQ) – 160 EU/ml for IgA and 4.6 (LoQ) – 160 EU/ml for IgG. Results are summarized below.

<table><tr><td rowspan=8 colspan=1>IgAIgG</td><td rowspan=1 colspan=1>Test Range(EU/ml)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept(95% CI)</td><td rowspan=1 colspan=1>R{2</td><td rowspan=1 colspan=1>% Recovery(Obtnd/Expctd)</td></tr><tr><td rowspan=1 colspan=1>7.4 to 41.6</td><td rowspan=1 colspan=1>1.01 (.92 to 1.10)</td><td rowspan=1 colspan=1>1.13 (-1.14 to 3.39)</td><td rowspan=1 colspan=1>0.9942</td><td rowspan=1 colspan=1>92% to 94%</td></tr><tr><td rowspan=1 colspan=1>2.3 to 97.2</td><td rowspan=1 colspan=1>1.04 (0.95 to 1.12)</td><td rowspan=1 colspan=1>1.45 (-3.18 to 6.08)</td><td rowspan=1 colspan=1>0.9935</td><td rowspan=1 colspan=1>90% to 96%</td></tr><tr><td rowspan=1 colspan=1>4.7 to 127.4</td><td rowspan=1 colspan=1>0.85 (0.79 to 0.91)</td><td rowspan=1 colspan=1>2.06 (-3.39 to 7.41)</td><td rowspan=1 colspan=1>0.9986</td><td rowspan=1 colspan=1>102% to 117%</td></tr><tr><td rowspan=1 colspan=1>Test Range(EU/ml)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept(95% CI)</td><td rowspan=1 colspan=1>R{2</td><td rowspan=1 colspan=1>% Recovery(Obtnd/Expctd)</td></tr><tr><td rowspan=1 colspan=1>9.0 to 47.0</td><td rowspan=1 colspan=1>0.98 (0.88 to 1.08)</td><td rowspan=1 colspan=1>0.87(-2.16 to 3.90)</td><td rowspan=1 colspan=1>0.9923</td><td rowspan=1 colspan=1>93% to 106%</td></tr><tr><td rowspan=1 colspan=1>12.7 to 116.8</td><td rowspan=1 colspan=1>0.98 (0.91 to 1.05)</td><td rowspan=1 colspan=1>-1.47(-6.66 to 3.73)</td><td rowspan=1 colspan=1>0.9951</td><td rowspan=1 colspan=1>102% to 110%</td></tr><tr><td rowspan=1 colspan=1>58.1 to 147.4</td><td rowspan=1 colspan=1>0.98 (0.87 to 1.08)</td><td rowspan=1 colspan=1>3.67 (-7.70 to 15.04)</td><td rowspan=1 colspan=1>0.9938</td><td rowspan=1 colspan=1>98% to 106%</td></tr></table>

To assess hook effect, dilutions of high positive specimens with results above the $1 6 0 \ : \mathsf { E U } / \mathsf { m l }$ measuring ranges were tested. Hook effect was not demonstrated in dilution samples as high as $\mathord { \sim } 5 , 5 1 5 . 8 \ E \cup / \mathrm { m l }$ for IgA and 1686.8 EU/ml for $\mathsf { I g G }$ within OD range of the microplate reader $( \sim 3 . 5 0 \mathsf { D } )$ .

# Interference

Interference was studied by mixing sera with known gliadin antibody levels for each isotype with potentially interfering serum samples and studying deviation from expected results. No significant interference was demonstrated for the following substances at the levels indicated: Hemoglobin $( 2 ~ \mathsf { g } / \mathsf { L } )$ , Bilirubin $( 3 4 2 \mu \mathrm { m o l / L } )$ , Rheumatoid Factor (100 EU/ml), Triglycerides (37 mmol/L), and Cholesterol (13 mmol/L).

Clinical Study: Sets of clinical samples were tested on the IMMCO Enhanced Gliadin ELISAs. By testing 250 celiac disease and 45 dermatitis herpetiformis along with 456 autoimmune and infectious disease controls following sensitivity and specificity were calculated. IgA deficient CD have been excluded from these calculations.

Borderline / indeterminate results are considered positive:

Celiac Disease IgA IgG Sensitivity $6 5 . 6 \%$ (95% CI 59.3% - 71.4%) 76.4% (95% CI 70.5% - 81.4%) Specificity $9 7 . 4 \%$ (95% CI 95.3% - 98.6%) 95.4% (95% CI 92.9% - 97.1%)

Dermatitis herpetiformis IgA IgG Sensitivity $3 5 . 6 \%$ $9 5 \%$ CI 22.3% - 51.3%) 57.8% (95% CI 42.2% - 72.0%) Specificity $9 7 . 4 \%$ (95% CI 95.3% - 98.6%) 95.4% (95% CI 92.9% - 97.1%)

Borderline / indeterminate results are considered negative: Celiac Disease IgA IgG Sensitivity $5 5 . 6 \%$ $9 5 \%$ CI 49.2% - 61.8%) 68.4% (95% CI 62.2% - 74.0%) Specificity $9 8 . 5 \%$ $( 9 5 \% \mathsf { C l } 9 6 . 7 \% - 9 9 . 3 \% )$ 96.7% (95% CI 94.5% - 98.1%)

Dermatitis herpetiformis IgA IgG Sensitivity $3 3 . 3 \%$ $9 5 \%$ CI 20.4% - 49.1%) 55.6% (95% CI 40.1% - 70.0%) Specificity $9 8 . 5 \%$ $9 5 \%$ CI 96.7% - 99.3%) $9 6 . 7 \%$ (95% CI 94.5% - 98.1%)

![](images/a85f8c81d814c354c934b05ee9069d977bd99f430ba1049ab8654b1dedbe7d18.jpg)

Kevin J. Lawson VP Regulatory Affairs